Declared Dividend • Jun 08
Dividend reduced to CN¥0.033 Dividend of CN¥0.033 is 76% lower than last year. Ex-date: 11th June 2026 Payment date: 11th June 2026 Dividend yield will be 0.4%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (14% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 78% to shift the payout ratio to a potentially unsustainable range, which is more than the 22% EPS decline seen over the last 5 years. Reported Earnings • Apr 29
Full year 2025 earnings released: EPS: CN¥0.16 (vs CN¥0.67 in FY 2024) Full year 2025 results: EPS: CN¥0.16 (down from CN¥0.67 in FY 2024). Revenue: CN¥1.54b (down 12% from FY 2024). Net income: CN¥63.2m (down 76% from FY 2024). Profit margin: 4.1% (down from 15% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Apr 29
Medicalsystem Biotechnology Co., Ltd, Annual General Meeting, May 22, 2026 Medicalsystem Biotechnology Co., Ltd, Annual General Meeting, May 22, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Ningbo, Zhejiang China Announcement • Mar 31
Medicalsystem Biotechnology Co., Ltd to Report Q1, 2026 Results on Apr 29, 2026 Medicalsystem Biotechnology Co., Ltd announced that they will report Q1, 2026 results on Apr 29, 2026 Announcement • Dec 31
Medicalsystem Biotechnology Co., Ltd to Report Fiscal Year 2025 Results on Apr 29, 2026 Medicalsystem Biotechnology Co., Ltd announced that they will report fiscal year 2025 results on Apr 29, 2026 New Risk • Nov 02
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 176% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.4% net profit margin). Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.01 (vs CN¥0.12 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.01 (down from CN¥0.12 in 3Q 2024). Revenue: CN¥399.4m (down 13% from 3Q 2024). Net income: CN¥3.70m (down 92% from 3Q 2024). Profit margin: 0.9% (down from 10.0% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 7% per year. Announcement • Sep 30
Medicalsystem Biotechnology Co., Ltd to Report Q3, 2025 Results on Oct 29, 2025 Medicalsystem Biotechnology Co., Ltd announced that they will report Q3, 2025 results on Oct 29, 2025 New Risk • Sep 16
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (275% cash payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (8.9% net profit margin). New Risk • Sep 07
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.9% Last year net profit margin: 14% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (275% cash payout ratio). Profit margins are more than 30% lower than last year (8.9% net profit margin). Announcement • Jul 02
Medicalsystem Biotechnology Co., Ltd to Report First Half, 2025 Results on Aug 29, 2025 Medicalsystem Biotechnology Co., Ltd announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • May 27
Medicalsystem Biotechnology Co., Ltd Approves Dividend for 2024 Medicalsystem Biotechnology Co. Ltd. at its AGM held on May 23, 2025 approved Cash dividend/10 shares (tax included): CNY 1.35000000 for 2024. Announcement • Apr 22
Medicalsystem Biotechnology Co., Ltd Proposes Final Cash Dividend for the Year 2024 Medicalsystem Biotechnology Co. Ltd. proposed final cash dividend of CNY 1.35000000 per 10 shares (tax included) for the year 2024. Announcement • Apr 20
Medicalsystem Biotechnology Co., Ltd, Annual General Meeting, May 23, 2025 Medicalsystem Biotechnology Co., Ltd, Annual General Meeting, May 23, 2025, at 14:00 China Standard Time. Location: 1F, Building 2, No. 1228, Jinda South Road, Yinzhou District, Ningbo, Zhejiang China Reported Earnings • Apr 19
Full year 2024 earnings released: EPS: CN¥0.67 (vs CN¥0.67 in FY 2023) Full year 2024 results: EPS: CN¥0.67 (in line with FY 2023). Revenue: CN¥1.74b (down 7.6% from FY 2023). Net income: CN¥258.0m (flat on FY 2023). Profit margin: 15% (up from 14% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Mar 31
Medicalsystem Biotechnology Co., Ltd to Report Q1, 2025 Results on Apr 26, 2025 Medicalsystem Biotechnology Co., Ltd announced that they will report Q1, 2025 results on Apr 26, 2025 Announcement • Dec 31
Medicalsystem Biotechnology Co., Ltd to Report Fiscal Year 2024 Results on Apr 19, 2025 Medicalsystem Biotechnology Co., Ltd announced that they will report fiscal year 2024 results on Apr 19, 2025 Reported Earnings • Oct 28
Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.14 in 3Q 2023). Revenue: CN¥457.6m (down 7.3% from 3Q 2023). Net income: CN¥45.9m (down 17% from 3Q 2023). Profit margin: 10.0% (down from 11% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥10.75, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 42% over the past three years. Announcement • Sep 30
Medicalsystem Biotechnology Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024 Medicalsystem Biotechnology Co., Ltd announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CN¥11.29, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 36x in the Biotechs industry in China. Total loss to shareholders of 34% over the past three years. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.27 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.25 (down from CN¥0.27 in 2Q 2023). Revenue: CN¥467.6m (down 3.8% from 2Q 2023). Net income: CN¥99.4m (down 3.9% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Jun 29
Medicalsystem Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024 Medicalsystem Biotechnology Co., Ltd announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • Jun 05
Dividend of CN¥0.13 announced Shareholders will receive a dividend of CN¥0.13. Ex-date: 7th June 2024 Payment date: 7th June 2024 Dividend yield will be 1.4%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 3.7% per year over the past 8 years. However, payments have been volatile during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Buy Or Sell Opportunity • May 10
Now 20% undervalued Over the last 90 days, the stock has risen 21% to CN¥10.72. The fair value is estimated to be CN¥13.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.9% over the last 3 years. Earnings per share has grown by 7.6%. Reported Earnings • Apr 20
Full year 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.52 in FY 2022) Full year 2023 results: EPS: CN¥0.67 (up from CN¥0.52 in FY 2022). Revenue: CN¥1.89b (down 24% from FY 2022). Net income: CN¥256.6m (up 29% from FY 2022). Profit margin: 14% (up from 8.0% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Announcement • Apr 20
Medicalsystem Biotechnology Co., Ltd, Annual General Meeting, May 24, 2024 Medicalsystem Biotechnology Co., Ltd, Annual General Meeting, May 24, 2024, at 14:00 China Standard Time. Location: No. 1228, Jinda South Road, Yinzhou District, Ningbo, Zhejiang China Announcement • Mar 30
Medicalsystem Biotechnology Co., Ltd to Report Q1, 2024 Results on Apr 24, 2024 Medicalsystem Biotechnology Co., Ltd announced that they will report Q1, 2024 results on Apr 24, 2024 Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥8.61, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 32x in the Biotechs industry in China. Total loss to shareholders of 48% over the past three years. Announcement • Dec 29
Medicalsystem Biotechnology Co., Ltd to Report Fiscal Year 2023 Results on Apr 19, 2024 Medicalsystem Biotechnology Co., Ltd announced that they will report fiscal year 2023 results on Apr 19, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.15 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.14 (down from CN¥0.15 in 3Q 2022). Revenue: CN¥493.8m (down 19% from 3Q 2022). Net income: CN¥55.1m (down 3.2% from 3Q 2022). Profit margin: 11% (up from 9.3% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Medicalsystem Biotechnology Co., Ltd to Report Q3, 2023 Results on Oct 26, 2023 Medicalsystem Biotechnology Co., Ltd announced that they will report Q3, 2023 results on Oct 26, 2023 Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.20 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.27 (up from CN¥0.20 in 2Q 2022). Revenue: CN¥485.9m (down 32% from 2Q 2022). Net income: CN¥103.5m (up 34% from 2Q 2022). Profit margin: 21% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Jul 01
Medicalsystem Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 19, 2023 Medicalsystem Biotechnology Co., Ltd. announced that they will report first half, 2023 results on Aug 19, 2023 Announcement • Jun 10
Medicalsystem Biotechnology Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 June 2023 Medicalsystem Biotechnology Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 1.05000000 for the year 2022, payable on 16 June 2023. Record date is 15 June 2023. Ex-date is 16 June 2023. Announcement • May 23
Medicalsystem Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2022 Medicalsystem Biotechnology Co., Ltd. approved cash dividend of CNY 1.05000000 per ten shares (tax included) for the year 2022, at its AGM held on May 19, 2023. Reported Earnings • Apr 28
Full year 2022 earnings released: EPS: CN¥0.52 (vs CN¥0.48 in FY 2021) Full year 2022 results: EPS: CN¥0.52 (up from CN¥0.48 in FY 2021). Revenue: CN¥2.49b (up 11% from FY 2021). Net income: CN¥198.5m (up 11% from FY 2021). Profit margin: 8.0% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Independent Director Li Cheng'ai was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.10 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.10 in 3Q 2021). Revenue: CN¥610.5m (up 1.8% from 3Q 2021). Net income: CN¥56.9m (up 44% from 3Q 2021). Profit margin: 9.3% (up from 6.6% in 3Q 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥12.58, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 34x in the Biotechs industry in China. Total loss to shareholders of 14% over the past three years. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.16 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.20 (up from CN¥0.16 in 2Q 2021). Revenue: CN¥713.2m (up 21% from 2Q 2021). Net income: CN¥77.0m (up 34% from 2Q 2021). Profit margin: 11% (up from 9.7% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Jun 01
Medicalsystem Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 8, 2022 Medicalsystem Biotechnology Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.95000000 on A shares for the year 2021. Record date is June 7, 2022. Ex-date is June 8, 2022. Payment date is June 8, 2022. Announcement • May 19
Medicalsystem Biotechnology Co., Ltd. Approves Cash Dividend for 2021 Medicalsystem Biotechnology Co., Ltd., at the Annual General Meeting held on 17 May 2022 approved Cash dividend/10 shares (tax included) of CNY 0.95000000 for 2021. Reported Earnings • Apr 27
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: EPS: CN¥0.18 (down from CN¥0.21 in 1Q 2021). Revenue: CN¥577.4m (up 8.7% from 1Q 2021). Net income: CN¥69.6m (down 7.9% from 1Q 2021). Profit margin: 12% (down from 14% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 1.6%. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Independent Director Li Cheng'ai was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Apr 26
Medicalsystem Biotechnology Co.,Ltd Announces Cash Dividend Proposal for the Year 2021 Medicalsystem Biotechnology Co.,Ltd announced on 25 April 2022 the profit distribution proposal for 2021 as follows: Cash dividend/10 shares (tax included) of CNY 0.95000000. Board Change • Jan 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Independent Director Li Cheng'ai was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥23.05, the stock trades at a trailing P/E ratio of 51.1x. Average trailing P/E is 51x in the Biotechs industry in China. Total returns to shareholders of 54% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.21 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥599.9m (down 4.9% from 3Q 2020). Net income: CN¥39.6m (down 46% from 3Q 2020). Profit margin: 6.6% (down from 12% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.18 in 2Q 2020) The company reported a poor second quarter result with weaker earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥590.1m (down 13% from 2Q 2020). Net income: CN¥57.5m (down 4.7% from 2Q 2020). Profit margin: 9.7% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥22.43, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 53x in the Biotechs industry in China. Total returns to shareholders of 23% over the past three years. Reported Earnings • Apr 29
Full year 2020 earnings released: EPS CN¥0.87 (vs CN¥1.63 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥2.30b (down 27% from FY 2019). Net income: CN¥299.5m (up CN¥859.4m from FY 2019). Profit margin: 13% (up from net loss in FY 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Announcement • Apr 29
Medicalsystem Biotechnology Co.,Ltd Announces Cash Dividend for the Year 2020 Medicalsystem Biotechnology Co.,Ltd announced cash dividend (tax included) of CNY 1.750 per 10 shares for the year 2020. Is New 90 Day High Low • Mar 11
New 90-day high: CN¥20.75 The company is up 4.0% from its price of CN¥20.03 on 11 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 6.0% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥17.90 The company is down 5.0% from its price of CN¥18.88 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Nov 23
New 90-day high: CN¥21.48 The company is up 6.0% from its price of CN¥20.21 on 25 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 13% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥465.9m, with earnings decreasing by CN¥705.5m from the prior year. Total revenue was CN¥2.53b over the last 12 months, down 20% from the prior year. Announcement • Sep 26
Medicalsystem Biotechnology Co.,Ltd announced that it expects to receive CNY 600 million in funding Medicalsystem Biotechnology Co.,Ltd (SZSE:300439) announced a private placement of not more than 103,590,786 A shares for gross proceeds of more than CNY 600,000,000 on June 28, 2020. The transaction will include participation from not more than 35 investors. The shares will have a face value of CNY 1 and will be issued at premium. The pricing base date of the transaction is the first day of the issue period, and the issue price is not less than 80% of the average price of the company's stocks 20 trading days before the first day of the issue period. The maximum number of issued shares does not exceed 30% of the company's total share capital before the issuance. The resolution of the issuance is valid for 12 months from the date and approval by the company's shareholders meeting. The securities will be issued subject to hold period of six months. The transaction has been approved at the 27th meeting of the 3rd directorate of the company on 28th June 2020, and are subject to the approval of the company's shareholders meeting and the China Securities Regulatory Commission. Announcement • Sep 19
Liu Peigang acquired unknown stake in Chongqing Hesheng Medical Devices Co., Ltd. from Medicalsystem Biotechnology Co.,Ltd (SZSE:300439) and Liu Ergang for CNY 37.8 million. Liu Peigang acquired unknown stake in Chongqing Hesheng Medical Devices Co., Ltd. from Medicalsystem Biotechnology Co.,Ltd (SZSE:300439) and Liu Ergang on September 10, 2019. Medicalsystem Biotechnology Co.,Ltd intends to transfer 21% of Chongqing Hesheng Medical Devices Co., Ltd. for CNY 37.8 million. Announcement • Sep 17
Yu Yingna agreed to acquire 71% stake in Medicalsystem Biotechnology (Zhoushan) Co., Ltd. from Medicalsystem Biotechnology Co.,Ltd (SZSE:300439) for CNY 35.5 million. Yu Yingna agreed to acquire 71% stake in Medicalsystem Biotechnology (Zhoushan) Co., Ltd. from Medicalsystem Biotechnology Co.,Ltd (SZSE:300439) for CNY 35.5 million on September 10, 2019. Payment will be done in one single installment within 10 days since signing of the agreement. After transfer, Medicalsystem Biotechnology Co.,Ltd will retain a 29% stake in Medicalsystem Biotechnology (Zhoushan) Co., Ltd. As of December 31, 2018, Medicalsystem Biotechnology (Zhoushan) Co., Ltd. has total assets of CNY 47.5 million, owners equity of CNY 47.5 million and net loss of CNY 2.5 million. Announcement • Aug 13
Medicalsystem Biotechnology Co.,Ltd to Report First Half, 2020 Results on Aug 28, 2020 Medicalsystem Biotechnology Co.,Ltd announced that they will report first half, 2020 results on Aug 28, 2020 
